381 related articles for article (PubMed ID: 27832973)
1. Neutralization of TNFα in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
Ji X; Peng Z; Li X; Yan Z; Yang Y; Qiao Z; Liu Y
Cancer Lett; 2017 Feb; 386():24-34. PubMed ID: 27832973
[TBL] [Abstract][Full Text] [Related]
2. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition.
Khan MA; Tania M; Wei C; Mei Z; Fu S; Cheng J; Xu J; Fu J
Oncotarget; 2015 Aug; 6(23):19580-91. PubMed ID: 26023736
[TBL] [Abstract][Full Text] [Related]
3. Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo.
Ji X; Han T; Kang N; Huang S; Liu Y
Life Sci; 2020 Nov; 260():118274. PubMed ID: 32827545
[TBL] [Abstract][Full Text] [Related]
4. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
[TBL] [Abstract][Full Text] [Related]
6. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
7. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Satram-Maharaj T; Nyarko JN; Kuski K; Fehr K; Pennington PR; Truitt L; Freywald A; Lukong KE; Anderson DH; Mousseau DD
Cell Signal; 2014 Dec; 26(12):2621-32. PubMed ID: 25152370
[TBL] [Abstract][Full Text] [Related]
8. Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1.
Li Y; Zhang Y; Liu X; Wang M; Wang P; Yang J; Zhang S
Int J Oncol; 2018 Jun; 52(6):2119-2129. PubMed ID: 29620169
[TBL] [Abstract][Full Text] [Related]
9. Taxifolin inhibits breast cancer cells proliferation, migration and invasion by promoting mesenchymal to epithelial transition via β-catenin signaling.
Li J; Hu L; Zhou T; Gong X; Jiang R; Li H; Kuang G; Wan J; Li H
Life Sci; 2019 Sep; 232():116617. PubMed ID: 31260685
[TBL] [Abstract][Full Text] [Related]
10. Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice.
Huang CC; Lo CP; Chiu CY; Shyur LF
Br J Pharmacol; 2010 Feb; 159(4):856-71. PubMed ID: 20105176
[TBL] [Abstract][Full Text] [Related]
11. Icariside II inhibits the EMT of NSCLC cells in inflammatory microenvironment via down-regulation of Akt/NF-κB signaling pathway.
Song J; Feng L; Zhong R; Xia Z; Zhang L; Cui L; Yan H; Jia X; Zhang Z
Mol Carcinog; 2017 Jan; 56(1):36-48. PubMed ID: 26859114
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
13. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
[TBL] [Abstract][Full Text] [Related]
14. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.
Ren Y; Zhou X; Yang JJ; Liu X; Zhao XH; Wang QX; Han L; Song X; Zhu ZY; Tian WP; Zhang L; Mei M; Kang CS
Cancer Lett; 2015 Jul; 362(2):174-82. PubMed ID: 25827073
[TBL] [Abstract][Full Text] [Related]
15. Oleuropein inhibits migration ability through suppression of epithelial-mesenchymal transition and synergistically enhances doxorubicin-mediated apoptosis in MCF-7 cells.
Choupani J; Alivand MR; M Derakhshan S; Zaeifizadeh M; S Khaniani M
J Cell Physiol; 2019 Jun; 234(6):9093-9104. PubMed ID: 30317622
[TBL] [Abstract][Full Text] [Related]
16. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
17. The antimetastatic effect and underlying mechanisms of thioredoxin reductase inhibitor ethaselen.
Zheng X; Chen Y; Bai M; Liu Y; Xu B; Sun R; Zeng H
Free Radic Biol Med; 2019 Feb; 131():7-17. PubMed ID: 30496814
[TBL] [Abstract][Full Text] [Related]
18. Specific chemotherapeutic agents induce metastatic behaviour through stromal- and tumour-derived cytokine and angiogenic factor signalling.
Liu G; Chen Y; Qi F; Jia L; Lu XA; He T; Fu Y; Li L; Luo Y
J Pathol; 2015 Oct; 237(2):190-202. PubMed ID: 25988668
[TBL] [Abstract][Full Text] [Related]
19. Fludioxonil induced the cancer growth and metastasis via altering epithelial-mesenchymal transition via an estrogen receptor-dependent pathway in cellular and xenografted breast cancer models.
Go RE; Kim CW; Jeon SY; Byun YS; Jeung EB; Nam KH; Choi KC
Environ Toxicol; 2017 Apr; 32(4):1439-1454. PubMed ID: 27539251
[TBL] [Abstract][Full Text] [Related]
20. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors.
Lee J; Hahm ER; Marcus AI; Singh SV
Mol Carcinog; 2015 Jun; 54(6):417-29. PubMed ID: 24293234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
